Beta Bionics, Inc. Common Stock (BBNX) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.41x
Beta Bionics, Inc. Common Stock (BBNX) has a Cash Flow-to-Debt Ratio of -0.41x as of June 2026, meaning its operating cash flow of $-14.62 Million could theoretically repay 0% of its total liabilities ($36.02 Million) in one year. See BBNX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.41x
Operating CF / Total Liabilities
Operating Cash Flow
$-14.62 Million
USD
Total Liabilities
$36.02 Million
USD
Data as of
Jun 2026
Most recent filing
Beta Bionics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Beta Bionics, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see BBNX cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Beta Bionics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Beta Bionics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.24x | $-50.92 Million | $41.13 Million | ▼ -88.8% |
| 2024 | -0.66x | $-48.27 Million | $73.63 Million | ▼ -3.9% |
| 2023 | -0.63x | $-32.45 Million | $51.43 Million | ▼ -115.4% |
| 2022 | -0.29x | $-60.21 Million | $205.56 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.